Roche: Tecentriq combo reduces lung cancer death risk

(CercleFinance.com) - Roche said on Monday a combination of Tecentriq plus Lilly's pemetrexed and chemotherapy reduced the risk of disease worsening or death by 40% compared with chemotherapy alone in people with non-squamous, non-small cell lung cancer.


A Phase III trial showed that Tecentriq and chemotherapy reduced the risk of disease worsening or death by 40% compared with chemotherapy alone.

But while a numerical improvement of 4.5 months for overall survival was observed, at this interim analysis statistical significance has not yet been met, Roche said.

The study will continue as planned, with final results expected next year.

The Roche share is currently down 1.1% at 232.6 Swiss francs.

Copyright (c) 2018 CercleFinance.com. All rights reserved.